For example, the treatment with CB1R antagonists such as SR141716 (5 mg/kg) increases CBF in the affected brain area, decreases the lesion volume in both the tMCAO and the photothrombotic permanent MCAO (pMCAO) models, and improves the neurological function after stroke (Zhang et al., 2008; Reichenbach et al., 2016). This evidence concerns the gene CNR1 and stroke disorder.